Clinical trial · Observational
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
NCT02247713CI-TRIAL-00015681PERTAINunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A part retrospective, part prospective cohort study to assess the difference in 2-year overall survival in patients with stage III NSCLC receiving chemoradiotherapy with curative intent in low and middle income countries before and after a training intervention on the use of PET/CT for radiotherapy treatment planning.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer Stage III | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Retrospective cohort
- description
- Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
- label
- Prospective cohort
- description
- Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
Primary outcomes (1)
- measure
- 2-year overall survival
- timeFrame
- the included patients will be followed for a maximum of 2 years
- description
- Determine the impact of PET/CT in RTP on 2-year overall survival rates for patients with stage III NSCLC receiving chemoradiotherapy with curative intent. Patients from the retrospective cohort will be selected from the institutional database and were treated between 2010 to 2013. Patients from the prospective cohort will be selected until the end of 2015.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically confirmed NSCLC * stage III as per local diagnostic protocol or agreement of local multidisciplinary team * available for clinical follow-up for at least 2 years * suitable for treatment with a radical target volume in the opinion of a radiation oncologist * ECOG performance 0 or 1 * signed informed consent * ability to commence radiation therapy within 4 weeks of acquisition of the RTP PET/CT * suitable for concurrent chemoradiotherapy (prospective cohort only) Exclusion Criteria: * other neoplasms in the last 5 years except non-melanoma skin cancer * stage IV disease diagnosed before acquisition of staging PET/CT * inability to provide informed consent * uncontrolled diabetes mellitus * pregnant or breast feeding mothers * tuberculosis * neo-adjuvant chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.